[go: up one dir, main page]

US20060051409A1 - Bezonatate liquid hard capsule dosage form - Google Patents

Bezonatate liquid hard capsule dosage form Download PDF

Info

Publication number
US20060051409A1
US20060051409A1 US10/936,378 US93637804A US2006051409A1 US 20060051409 A1 US20060051409 A1 US 20060051409A1 US 93637804 A US93637804 A US 93637804A US 2006051409 A1 US2006051409 A1 US 2006051409A1
Authority
US
United States
Prior art keywords
hard capsule
benzonatate
bottom half
pharmaceutical dosage
bezonatate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/936,378
Inventor
Pieter Groenewoud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mikart Inc
Original Assignee
Mikart Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mikart Inc filed Critical Mikart Inc
Priority to US10/936,378 priority Critical patent/US20060051409A1/en
Assigned to MIKART, INC. reassignment MIKART, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GROENEWOUD, PIETER J.
Publication of US20060051409A1 publication Critical patent/US20060051409A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material

Definitions

  • the present invention relates to pharmaceutical dosages and, more specifically, to a pharmaceutical dosage that includes benzonatate in a hard capsule.
  • Benzonatate a known composition used as an antitussive, is manufactured in liquid form. Typically, dosages of benzonatate are placed in a soft gel cap. Some patients, especially children, have a tendency to bite into soft gel caps, expecting them to taste like candy. When bitten hard enough, the liquid in the gel cap is released into the patient's mouth. Benzonatate causes local anesthesia in the mouth and throat. This local anesthesia can lead to choking in certain patients. Therefore, there is a need for benzonatate in a form with a reduced likelihood of being released in the patient's mouth.
  • gel caps are relatively expensive to produce, requiring solvents to provide the proper finish.
  • Typical solvents used include methylene chloride, which is an undesirable material in the finished gel cap and may have undesirable environmental consequences.
  • the present invention which, in one aspect, is a pharmaceutical dosage that includes benzonatate, in liquid form, disposed in a hard capsule.
  • the invention is a pharmaceutical dosage that includes a hard capsule, benzonatate and a sealer ring.
  • the hard capsule has a bottom half and a top half that covers the bottom half.
  • the benzonatate is in liquid form and is disposed in the bottom half of the hard capsule.
  • the sealer ring seals the top half to the bottom half.
  • the invention is a method of making a pharmaceutical dosage, in which liquid benzonatate is placed in a hard capsule.
  • the hard capsule is sealed with the liquid benzonatate therein.
  • FIG. 1 is a side elevational view of one illustrative embodiment of the invention.
  • FIG. 2 is a side elevational view of a second illustrative embodiment of the invention.
  • a pharmaceutical dosage 100 that discourages biting includes a hard capsule 110 and liquid form benzonatate 102 that is placed in the hard capsule 110 .
  • the hard capsule 110 includes a bottom half 114 , into which the benzonatate is disposed and a top half 112 , that covers a portion of the bottom half 114 .
  • a sealer ring 116 may be used to seal the top half 112 to the bottom half 114 .
  • One type of sealing machine that may be used to apply the sealer ring includes the S-40 HICAPSEAL, available from Shionogi Qualicaps, Inc., 6505 Franz Warner Parkway, Whitsett, N.C. 27377.
  • the hard capsule 110 could be made from materials such as: gelatin, gelatin and polyethylene glycol, and hypromellose.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

A pharmaceutical dosage includes a hard capsule, benzonatate and a sealer ring. The hard capsule has a bottom half and a top half that covers the bottom half. The benzonatate is in liquid form and is placed in the bottom half of the hard capsule. The sealer ring seals the top half to the bottom half.

Description

    BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The present invention relates to pharmaceutical dosages and, more specifically, to a pharmaceutical dosage that includes benzonatate in a hard capsule.
  • 2. Description of the Prior Art
  • Benzonatate, a known composition used as an antitussive, is manufactured in liquid form. Typically, dosages of benzonatate are placed in a soft gel cap. Some patients, especially children, have a tendency to bite into soft gel caps, expecting them to taste like candy. When bitten hard enough, the liquid in the gel cap is released into the patient's mouth. Benzonatate causes local anesthesia in the mouth and throat. This local anesthesia can lead to choking in certain patients. Therefore, there is a need for benzonatate in a form with a reduced likelihood of being released in the patient's mouth.
  • Also, gel caps are relatively expensive to produce, requiring solvents to provide the proper finish. Typical solvents used include methylene chloride, which is an undesirable material in the finished gel cap and may have undesirable environmental consequences.
  • Therefore, there is a need for a benzonatate dosage form that has a lower likelihood of being bitten into.
  • SUMMARY OF THE INVENTION
  • The disadvantages of the prior art are overcome by the present invention which, in one aspect, is a pharmaceutical dosage that includes benzonatate, in liquid form, disposed in a hard capsule.
  • In another aspect, the invention is a pharmaceutical dosage that includes a hard capsule, benzonatate and a sealer ring. The hard capsule has a bottom half and a top half that covers the bottom half. The benzonatate is in liquid form and is disposed in the bottom half of the hard capsule. The sealer ring seals the top half to the bottom half.
  • In yet another aspect, the invention is a method of making a pharmaceutical dosage, in which liquid benzonatate is placed in a hard capsule. The hard capsule is sealed with the liquid benzonatate therein.
  • These and other aspects of the invention will become apparent from the following description of the preferred embodiments taken in conjunction with the following drawings. As would be obvious to one skilled in the art, many variations and modifications of the invention may be effected without departing from the spirit and scope of the novel concepts of the disclosure.
  • BRIEF DESCRIPTION OF THE FIGURES OF THE DRAWINGS
  • FIG. 1 is a side elevational view of one illustrative embodiment of the invention.
  • FIG. 2 is a side elevational view of a second illustrative embodiment of the invention.
  • DETAILED DESCRIPTION OF THE INVENTION
  • A preferred embodiment of the invention is now described in detail. Referring to the drawings, like numbers indicate like parts throughout the views. As used in the description herein and throughout the claims, the following terms take the meanings explicitly associated herein, unless the context clearly dictates otherwise: the meaning of “a,” “an,” and “the” includes plural reference, the meaning of “in” includes “in” and “on.”
  • As shown in FIGS. 1 and 2, a pharmaceutical dosage 100 that discourages biting includes a hard capsule 110 and liquid form benzonatate 102 that is placed in the hard capsule 110. The hard capsule 110 includes a bottom half 114, into which the benzonatate is disposed and a top half 112, that covers a portion of the bottom half 114.
  • A sealer ring 116 may be used to seal the top half 112 to the bottom half 114. One type of sealing machine that may be used to apply the sealer ring includes the S-40 HICAPSEAL, available from Shionogi Qualicaps, Inc., 6505 Franz Warner Parkway, Whitsett, N.C. 27377. As is generally known in the pharmaceutical arts, the hard capsule 110 could be made from materials such as: gelatin, gelatin and polyethylene glycol, and hypromellose.
  • The above described embodiments are given as illustrative examples only. It will be readily appreciated that many deviations may be made from the specific embodiments disclosed in this specification without departing from the invention. Accordingly, the scope of the invention is to be determined by the claims below rather than being limited to the specifically described embodiments above.

Claims (8)

1. A pharmaceutical dosage, comprising:
a. a hard capsule; and
b. benzonatate, in liquid form, disposed in the hard capsule.
2. The pharmaceutical dosage of claim 1, wherein the hard capsule comprises:
a. a bottom half, into which the benzonatate is disposed;
b. a top half, that covers a portion of the bottom half;
c. a sealer ring that seals the top half to the bottom half.
3. The pharmaceutical dosage of claim 1, wherein the hard capsule comprises gelatin.
4. The pharmaceutical dosage of claim 1, wherein the hard capsule comprises gelatin and polyethylene glycol.
5. The pharmaceutical dosage of claim 1, wherein the hard capsule comprises hypromellose.
6. A pharmaceutical dosage, comprising:
a. a hard capsule, having a bottom half and a top half that covers a portion of the bottom half;
b. benzonatate, in liquid form, disposed in the bottom half of the hard capsule; and
c. a sealer ring that seals the top half to the bottom half.
7. A method of making a pharmaceutical dosage, comprising the steps of:
a. placing liquid benzonatate in a hard capsule; and
b. sealing the hard capsule with the liquid benzonatate therein.
8. The method of claim 7, wherein the sealing step comprises applying a sealer ring to the capsule.
US10/936,378 2004-09-08 2004-09-08 Bezonatate liquid hard capsule dosage form Abandoned US20060051409A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/936,378 US20060051409A1 (en) 2004-09-08 2004-09-08 Bezonatate liquid hard capsule dosage form

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/936,378 US20060051409A1 (en) 2004-09-08 2004-09-08 Bezonatate liquid hard capsule dosage form

Publications (1)

Publication Number Publication Date
US20060051409A1 true US20060051409A1 (en) 2006-03-09

Family

ID=35996530

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/936,378 Abandoned US20060051409A1 (en) 2004-09-08 2004-09-08 Bezonatate liquid hard capsule dosage form

Country Status (1)

Country Link
US (1) US20060051409A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109394724A (en) * 2013-12-21 2019-03-01 石药集团恩必普药业有限公司 A kind of butylphthalide liquid hard capsule preparation and preparation method thereof
WO2019199830A1 (en) * 2018-04-10 2019-10-17 Stem Arts Projects, Llc Capsule for lyophilized reagent storage and delivery

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975426A (en) * 1987-06-08 1990-12-04 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6793934B1 (en) * 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975426A (en) * 1987-06-08 1990-12-04 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6793934B1 (en) * 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109394724A (en) * 2013-12-21 2019-03-01 石药集团恩必普药业有限公司 A kind of butylphthalide liquid hard capsule preparation and preparation method thereof
CN109394724B (en) * 2013-12-21 2021-07-30 石药集团恩必普药业有限公司 A kind of butylphthalide liquid hard capsule preparation and preparation method thereof
WO2019199830A1 (en) * 2018-04-10 2019-10-17 Stem Arts Projects, Llc Capsule for lyophilized reagent storage and delivery
EP3607297A4 (en) * 2018-04-10 2020-12-23 Stem Arts Projects, LLC Capsule for lyophilized reagent storage and delivery
US10927402B2 (en) 2018-04-10 2021-02-23 Stem Arts Projects, Llc Capsule for lyophilized reagent storage and delivery

Similar Documents

Publication Publication Date Title
US5464631A (en) Encapsulated dosage forms
ES2567068T3 (en) Enema with reduced irritation for the treatment of inflammatory bowel disease (IBD)
CA2341024A1 (en) Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture
TW201028140A (en) Pharmaceutical dosages delivery system
US20050053648A1 (en) Medication delivery device
ATE194290T1 (en) STABILIZED COMPOSITION FOR ORAL ADMINISTRATION OF PEPTIDES
KR20150036553A (en) Laquinimod Formulations without Alkalizing Agent
CN1956736A (en) Oral preparations
US20060051409A1 (en) Bezonatate liquid hard capsule dosage form
HUT57578A (en) Process for producing tablet-capsule combination
CN106619128A (en) Sealed storage composition for capsule and sealed storage method thereof
US20060293641A1 (en) Housing body for deglutition of solid molding for oral ingestion, container for the housing body, and deglutition method
CN113164405A (en) Hydroxypropyl methylcellulose hollow capsule
US20140224680A1 (en) Kit-of-parts
US5626872A (en) Pharmaceutical soft capsules containing lysine clonixinate and a process for their preparation
US20180369154A1 (en) Acid-resistant capsule
CN206867447U (en) A kind of Capsules
CN219354686U (en) Anti-brittleness gelatin hollow capsule
US20180200191A1 (en) Multi Component Pill and Method(s) of Use
KR850002400A (en) Methods for Continuous Release of Medicines and Continuously Released Medicine Products
CN208037164U (en) Portable medicine taking auxiliary reagent box
ATE383097T1 (en) DOSAGE FORM FOR THE ORAL ADMINISTRATION OF ACTIVE INGREDIENTS, VITAMINS AND/OR NUTRIENTS
US20060222700A1 (en) Tablet and capsule form of liquid active ingredient
CN205659160U (en) Good capsule of leakproofness
IL105870A (en) Pharmaceutical soft capsules containing lysine clonixinate and their preparation

Legal Events

Date Code Title Description
AS Assignment

Owner name: MIKART, INC., GEORGIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GROENEWOUD, PIETER J.;REEL/FRAME:015737/0889

Effective date: 20041011

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION